(Q46593736)

23 December 2017

title

Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice (English)

1 reference

23 December 2017

author

Jorma Hinkula

1

1 reference

23 December 2017

Britta Wahren

3

object named as

Britta Wahren

1 reference

23 December 2017

author name string

Marie Hagbom

2

1 reference

23 December 2017

Ulf Schroder

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

25 April 2008

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

26

1 reference

23 December 2017

issue

40

1 reference

23 December 2017

page(s)

5101-5106

1 reference

23 December 2017

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

DNA-plasmids of HIV-1 induce systemic and mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Genetic immunization is augmented by murine polyomavirus VP1 pseudocapsids

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

inferred from DOI database lookup

7 January 2021

based on heuristic

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.098

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.03.098

1 reference

23 December 2017

release_6hysee6vkvarvbg3el2pja5hre

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6hysee6vkvarvbg3el2pja5hre

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 December 2017